Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ABIONYX Pharma

ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease
From ABIONYX Pharma
Via Business Wire
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
From ABIONYX Pharma
Via Business Wire
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
From ABIONYX Pharma
Via Business Wire
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
From ABIONYX Pharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.